198 related articles for article (PubMed ID: 36403197)
1. TTI1 promotes non-small-cell lung cancer progression by regulating the mTOR signaling pathway.
Zhang LX; Yang X; Wu ZB; Liao ZM; Wang DG; Chen SW; Lu F; Wu YB; Zhu SQ
Cancer Sci; 2023 Mar; 114(3):855-869. PubMed ID: 36403197
[TBL] [Abstract][Full Text] [Related]
2. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer.
Li J; Cheng D; Zhu M; Yu H; Pan Z; Liu L; Geng Q; Pan H; Yan M; Yao M
Theranostics; 2019; 9(1):179-195. PubMed ID: 30662561
[TBL] [Abstract][Full Text] [Related]
3. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
5. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
[TBL] [Abstract][Full Text] [Related]
6. CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer.
Zhu J; Cai T; Zhou J; Du W; Zeng Y; Liu T; Fu Y; Li Y; Qian Q; Yang XH; Li Q; Huang JA; Liu Z
J Exp Clin Cancer Res; 2021 Jun; 40(1):192. PubMed ID: 34108040
[TBL] [Abstract][Full Text] [Related]
7. Role of eIF3C Overexpression in Predicting Prognosis of Intrahepatic Cholangiocarcinoma.
Xu YP; Dong ZN; Zhou YQ; Zhao YJ; Zhao Y; Wang F; Huang XY; Guo CY
Dig Dis Sci; 2022 Feb; 67(2):559-568. PubMed ID: 33576946
[TBL] [Abstract][Full Text] [Related]
8. Tastin promotes non-small-cell lung cancer progression through the ErbB4, PI3K/AKT, and ERK1/2 pathways.
Yue A; Chen M; Dai S; Zhang Y; Wei W; Fan L; Wang F; Zhang F; Yu H; Lu Y; Lei Y
Exp Biol Med (Maywood); 2023 Mar; 248(6):519-531. PubMed ID: 36691332
[TBL] [Abstract][Full Text] [Related]
9. FKBP4 Accelerates Malignant Progression of Non-Small-Cell Lung Cancer by Activating the Akt/mTOR Signaling Pathway.
Meng W; Meng J; Jiang H; Feng X; Wei D; Ding Q
Anal Cell Pathol (Amst); 2020; 2020():6021602. PubMed ID: 33354489
[TBL] [Abstract][Full Text] [Related]
10. Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma.
Hao XL; Tian Z; Han F; Chen JP; Gao LY; Liu JY
Pathol Res Pract; 2019 Jul; 215(7):152438. PubMed ID: 31126818
[TBL] [Abstract][Full Text] [Related]
11. Novel long non-coding RNA LBX2-AS1 indicates poor prognosis and promotes cell proliferation and metastasis through Notch signaling in non-small cell lung cancer.
Tang LX; Su SF; Wan Q; He P; Xhang Y; Cheng XM
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7419-7429. PubMed ID: 31539129
[TBL] [Abstract][Full Text] [Related]
12. Expression Signature and Role of miR-30d-5p in Non-Small Cell Lung Cancer: a Comprehensive Study Based on in Silico Analysis of Public Databases and in Vitro Experiments.
Gao L; He RQ; Wu HY; Zhang TT; Liang HW; Ye ZH; Li ZY; Xie TT; Shi Q; Ma J; Hu XH; Chen G
Cell Physiol Biochem; 2018; 50(5):1964-1987. PubMed ID: 30396166
[TBL] [Abstract][Full Text] [Related]
13. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
[TBL] [Abstract][Full Text] [Related]
14. Hsa_circ_0016760 exacerbates the malignant development of non‑small cell lung cancer by sponging miR‑145‑5p/FGF5.
Zhu Z; Wu Q; Zhang M; Tong J; Zhong B; Yuan K
Oncol Rep; 2021 Feb; 45(2):501-512. PubMed ID: 33416186
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated
Sui J; Zhao Q; Zhang Y; Liang G
DNA Cell Biol; 2022 Mar; 41(3):319-329. PubMed ID: 35244469
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
18. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
Tang Y; Xiao G; Chen Y; Deng Y
Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897
[TBL] [Abstract][Full Text] [Related]
19. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.
Wang L; Yue W; Zhang L; Zhao X; Wang Y; Xu S
Surg Today; 2012 May; 42(5):419-25. PubMed ID: 22127531
[TBL] [Abstract][Full Text] [Related]
20. Effects of microRNA-513b on cell proliferation, apoptosis, invasion, and migration by targeting HMGB3 through regulation of mTOR signaling pathway in non-small-cell lung cancer.
Wang J; Sheng Z; Cai Y
J Cell Physiol; 2019 Jul; 234(7):10934-10941. PubMed ID: 30623409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
